NSCLC patients who received concurrent EGFR tyrosine kinase inhibitors (TKIs) had an increased of 12-month cumulative incidence of RN (15.6 vs. 6%, p = 0.04) as compared to other patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.